Risk of Ischemic Stroke and Decreased Serum Bilirubin Levels
Is There a Causal Link?
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Bilirubin, often thought to be a toxic end product of heme, is a potent antioxidant compound in vivo.1,2
As shown in the schematic Figure, degraded red blood cells release heme, which is broken down by heme oxygenase to biliverdin, which is reduced by biliverdin reductase into the hydrophobic compound bilirubin. Unconjugated bilirubin is a lipid-soluble molecule that must be made water soluble to be excreted. Unconjugated bilirubin is carried by albumin to the liver, where it is conjugated into a water-soluble form by hepatic glucuronyl transferase. The hepatic enzyme UDP-glucuronyl transferase 1A1 (UGT1A1) converts bilirubin to a soluble (conjugated) form suitable for renal and biliary elimination.1,2 Importantly, in healthy European populations, common genetic variation of the UGT1A1 promoter region explains ≈50% of the variability in serum total (TB) and conjugated bilirubin levels.3 UGT1A1 is also responsible for the glucuronidation of many other small lipophilic molecules, such as steroid hormones and drugs that affect the vasculature.1,2
See accompanying article on page 946
Currently, ample evidence suggests that lower levels of TB are associated with increased risk of cardiovascular disease (CVD), independently of traditional risk factors.4–9 In 2012, further evidence for a possible beneficial role of bilirubin protecting against CVD was provided from a large UK primary care database (n=130 052 patients) with the measurement of TB levels recorded 3 months before first statin treatment. After a median of …